Moderna Inc. (NASDAQ:MRNA) on Friday reported a fourth-quarter loss of $2.11, beating the expected loss of $2.59, lower than a loss of $2.91 a year ago.
The COVID-19 vaccine maker reported quarterly sales of $678 million, topping the expected $626.097 million.
Total revenue was on the higher end of the company’s prior expectations and was driven primarily by COVID vaccine sales.
Product sales were $264 million in the U.S. and $381 million in international markets. Fourth quarter revenue decreased 30% year over year, primarily reflecting lower COVID vaccine sales volume compared to the prior-year period.
“In 2025, we sharpened our commercial execution, launched our third product, and brought online three international manufacturing sites, while advancing our mRNA pipeline. At the same time, we lowered our annual operating expenses by approximately $2.2 billion, significantly surpassing our cost-reduction targets,” said Stéphane Bancel, CEO of Moderna.
“We entered the new year with strong momentum despite the continued challenging environment in the U.S., poised to deliver up to 10 percent revenue growth through mNEXSPIKE expansion and our international strategic partnerships,” Bancel said on Friday.
Outlook
Turning to guidance, Moderna is targeting up to 10% revenue growth from $1.94 billion in 2025 and expects the 2026 revenue split to be approximately 50% U.S. and approximately 50% international.
Cost of sales …